Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment

BMC Infectious Diseases

Research

Yasumasa Kakei¹  Ichiro Morioka²  Tetsushi Yoshikawa³  Kazumichi Fujioka⁴  Hiroyuki Moriuchi⁵  Yuka Torii⁶  Yoshinori Ito⁷  Naoto Takahashi⁸  Yu Kakimoto⁸  Akira Oka⁹ 

[1]Clinical and Translational Research Center, Kobe University Hospital, 650-0017, Kobe, Japan

[2]Department of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-cho, Itabashi-ku, 173-8610, Tokyo, Japan

[3]Department of Pediatrics, Fujita Health University School of Medicine, 470-1192, Toyoake, Japan

[4]Department of Pediatrics, Kobe University Graduate School of Medicine, 650-0017, Kobe, Japan

[5]Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, 852-8501, Nagasaki, Japan

[6]Department of Pediatrics, Nagoya University Graduate School of Medicine, 466-8550, Nagoya, Japan

[7]Department of Pediatrics, Nagoya University Graduate School of Medicine, 466-8550, Nagoya, Japan

[8]Department of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-cho, Itabashi-ku, 173-8610, Tokyo, Japan

[9]Department of Pediatrics, The University of Tokyo, 113-8655, Tokyo, Japan

[10]Department of Pediatrics, The University of Tokyo, 113-8655, Tokyo, Japan

[11]Saitama Prefectural Children’s Medical Center, 330-8777, Saitama, Japan

关键词: Congenital CMV infection;    PCR;    Plasma;    Valganciclovir;    Whole blood;   

DOI  :  10.1186/s12879-023-07995-6

 received in 2022-07-16, accepted in 2023-01-09,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundCongenital cytomegalovirus (CMV) infection (cCMV) can cause sensorineural hearing loss and neurodevelopmental disabilities in children. Oral valganciclovir (VGCV) therapy has been reported to improve long-term audiological and neurodevelopmental outcomes in patients with cCMV. The levels of CMV DNA in whole blood have been monitored in previous studies. However, quantitative methods using whole blood have not been standardized. Recently, the plasma viral load has been standardized and widely used in CMV-associated diseases.MethodsCMV viral loads in whole blood and plasma were serially measured in 24 patients with a confirmatory diagnosis of cCMV during oral VGCV therapy using an in-house real-time PCR assay. Plasma samples were assayed using the Cobas 6800 system (Roche Diagnostics) in addition to an in-house assay.ResultsPlasma CMV viral loads were remarkably decreased at the end of therapy compared to before therapy. A significant correlation of CMV levels between whole blood and plasma was observed (Spearman’s ρ = 0.566). The levels of CMV DNA before therapy were significantly correlated with the period of decreasing the viral loads to below the detection limit, not only in whole blood (Spearman’s ρ = 0.901) but also in plasma (Spearman, ρ = 0.804). Finally, CMV viral loads between the in-house assay and commercially available standardized assay in 75 plasma samples with positive PCR results for CMV were compared; a significant correlation was observed between the results of both assays.ConclusionsThere was a significant correlation between the two assays (Spearman, ρ = 0.882), suggesting that CMV plasma viral loads measured by the standardized assay are widely used to monitor the levels of CMV DNA in patients with cCMV during oral VGCV therapy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

Fig. 4

41116_2022_35_Article_IEq95.gif